Work

Pcn127 Cost-effectiveness Analysis of Nivolumab in Combination With Ipilimumab Compared With Currently Available First-line Treatments in Patients With Previously Untreated Metastatic Renal Cell Carcinoma in the United States

Year: 2019

Type: conference-abstract

Source: Value in Health

DOI: 10.1016/j.jval.2019.04.251

Authors: N. Tanova, S. Yang, L.H. Cheung, V. Genestier, K.M. Gooden, B. Malcolm, S. Rao, T.K. Choueiri

Institutions: Bristol-Myers Squibb (United States), Dana-Farber Cancer Institute

Language: English

Topic: Health Systems, Economic Evaluations, Quality of Life

Subfield: Economics and Econometrics

Field: Economics, Econometrics and Finance

Domain: Social Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2953586793

Cites:

Cited by:

Related to: 10